Dave Ricks

“We delivered robust revenue across all key products and major geographies. We raised our our full year annual guidance, we advanced our pipeline across each of our therapeutic areas and expanded our pipeline through business development.”

“During the quarter, we delivered robust revenue growth, advanced our pipeline across all four therapeutic areas, announced multiple business development transactions, and invested to drive our future growth.”

“We delivered robust revenue growth, advanced our pipeline, expanded our manufacturing footprint, and helped over 70 million people around the world.”

“We increased our revenue, advanced our pipeline, invested to drive future growth, and shared the first Phase 3 clinical data from our oral GLP-1 orforglipron. Dan will share more details during the R&D update, but we're pleased with the results from the GLP-1 trial for orforglipron in patients with Type 2 diabetes.”

“In Q3, Lilly continued to make progress across the business. We delivered strong revenue growth. We advanced and expanded our pipeline and we invested in new product launches and continued expanding manufacturing network.”